08 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/08/3146057/0/en/NeuroNOS-Granted-FDA-Orphan-Drug-Designation-for-Glioblastoma-the-Most-Common-and-Deadliest-Primary-Malignant-Brain-Cancer-in-Adults.html
12 May 2025
// FDA
06 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/06/3038114/0/en/Allarity-Therapeutics-Announces-Phase-2-Trial-of-Stenoparib-in-Combination-with-Temozolomide-for-Recurrent-Small-Cell-Lung-Cancer-Fully-Funded-by-the-US-Veterans-Administration.html
14 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/nanopharmaceutics-and-northwestern-university-announce-initiation-of-phase-i-adaptive-dose-escalation-clinical-study-with-dose-expansion-of-oral-triapine-in-combination-with-temozolomide-tmz-for-patients-with-recurrent-glioblas-302145367.html
18 Apr 2023
// BUSINESSWIRE
17 Jan 2023
// ECONOMIC TIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nppa-revises-ceiling-prices-of-128-formulations/articleshow/97033906.cms